CN112190649A - Medicine for adjuvant therapy of cervical cancer and preparation method thereof - Google Patents

Medicine for adjuvant therapy of cervical cancer and preparation method thereof Download PDF

Info

Publication number
CN112190649A
CN112190649A CN202011244548.2A CN202011244548A CN112190649A CN 112190649 A CN112190649 A CN 112190649A CN 202011244548 A CN202011244548 A CN 202011244548A CN 112190649 A CN112190649 A CN 112190649A
Authority
CN
China
Prior art keywords
parts
cervical cancer
medicine
medicament
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011244548.2A
Other languages
Chinese (zh)
Inventor
文怡海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202011244548.2A priority Critical patent/CN112190649A/en
Publication of CN112190649A publication Critical patent/CN112190649A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/586—Turtles; Tortoises, e.g. terrapins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Husbandry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a medicine for adjuvant therapy of cervical cancer and a preparation method thereof. The medicine comprises the following components in parts by mass: 20-50 parts of astragalus membranaceus, 15-20 parts of bighead atractylodes rhizome, 15-20 parts of poria cocos, 5-10 parts of scorpion, 5-10 parts of ligusticum wallichii, 8-12 parts of paniculate swallowwort root, 7-12 parts of rhizoma notopterygii, 15-20 parts of turtle shell, 15-20 parts of oyster, 5-10 parts of radix bupleuri, 7-12 parts of radix paeoniae alba, 10-15 parts of sida acuta, 10-15 parts of paris polyphylla, 3-5 parts of prepared monkshood, 5-10 parts of aspongopus and 10-20 parts of emilia sonchifolia. The medicine disclosed by the invention can strengthen the immune function, dissipate hardness and soften knot, dredge collaterals and relieve pain, clear away heat and toxic materials, cool blood, sooth liver and relieve depression, promote yang qi and has a unique curative effect on cervical cancer.

Description

Medicine for adjuvant therapy of cervical cancer and preparation method thereof
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a medicine for adjuvant therapy of cervical cancer and a preparation method thereof.
Background
Malignant tumors are a relatively intractable class of diseases in clinical treatment. The malignant tumor is easy to have serious dyscrasia, so that the malignant tumor has great harm to the health of people.
Currently, the main treatment modalities for cancer include surgery, chemotherapy and/or radiotherapy. However, the above treatment method can cause damage to healthy cells while removing cancer cells, and it is known that chemotherapy and radiotherapy also bring obvious side effects, causing great pain to patients. In recent years, medical attention has been gradually paid to the treatment of malignant tumors by the traditional Chinese medicine therapy, which is increasingly applied clinically due to the advantages of small side effects and low treatment cost and obtains better curative effects. Aiming at the defects of unstable curative effect, obvious treatment side effect, high cost and the like of the existing western medicine for treating malignant tumor, the existing medicine for treating malignant tumor is an important subject of the research of the traditional Chinese medicine and pharmacy.
Disclosure of Invention
The invention aims to provide a medicine for adjuvant therapy of cervical cancer and a preparation method thereof, and the medicine has a remarkable inhibition effect on cervical cancer, and has the advantages of obvious curative effect, strong applicability, small toxic and side effects and low cost.
The medicine for adjuvant therapy of cervical cancer comprises the following components in parts by mass:
20-50 parts of astragalus membranaceus, 15-20 parts of bighead atractylodes rhizome, 15-20 parts of poria cocos, 5-10 parts of scorpion, 5-10 parts of ligusticum wallichii, 8-12 parts of paniculate swallowwort root, 7-12 parts of rhizoma notopterygii, 15-20 parts of turtle shell, 15-20 parts of oyster, 5-10 parts of radix bupleuri, 7-12 parts of radix paeoniae alba, 10-15 parts of sida acuta, 10-15 parts of paris polyphylla, 3-5 parts of prepared monkshood, 5-10 parts of aspongopus and 10-20 parts of emilia sonchifolia.
The preparation method of the medicine for adjuvant therapy of cervical cancer comprises the following steps:
weighing the components in parts by weight, respectively grinding the components to 50-100 meshes, and uniformly mixing to obtain the medicine for the adjuvant treatment of cervical cancer.
The second preparation method of the medicine for adjuvant therapy of cervical cancer comprises the following steps:
weighing the components in parts by weight, adding hot water for soaking, heating to boil, decocting, filtering and drying to obtain dry medicine powder, and grinding to 50-100 meshes to obtain the medicine for adjuvant treatment of cervical cancer.
Preferably, the amount of the hot water is 8 to 12 times of the total weight of the ingredients.
Preferably, the hot water temperature is 50-90 ℃.
Preferably, the soaking time is 1-2 hours.
Preferably, the decocting time is 1.5-3 hours.
A pharmaceutical preparation is a capsule, a pill, a granule, a tablet or oral liquid, comprises the medicine for adjuvant therapy of cervical cancer and auxiliary materials necessary for preparation molding, and can be prepared according to a conventional pharmaceutical preparation method.
The mechanism in the invention is as follows:
(1) the astragalus root, combined with the tuckahoe and the atractylodes macrocephala as monarch drugs, can tonify qi, invigorate spleen, promote diuresis, activate the self-defense ability of an immune system and improve the immune function; the Sichuan feet, the scorpion, the ground beetle, the turtle shell, the aspongopus and the oyster are substances with blood, flesh and emotion and are used as ministerial drugs, have the effects of strengthening life bodies and wild functions, can attack visible substances in bodies, penetrate deep layers of internal organs, dissipate hard masses, soften nodes, reduce phlegm, dredge collaterals, relieve pain, counteract poison and expel toxin. Sida acuta, paris polyphylla, radix bupleuri and radix paeoniae alba are used as adjuvant drugs, and the drugs have the effects of clearing heat, activating blood, expelling blood toxin, soothing liver, relieving depression, promoting qi circulation and calming the liver. Prepared aconite root, radix Aconiti lateralis Preparata promotes yang qi of human body, has the effect of warming kidney, and can protect the root of human life, and is used as a guiding drug. After combining the efficacies of various medicines, the medicine can act on human body synergistically and exert greater effect. The compatibility standard of the medicines is designed and prepared by taking the characteristics of cervical cancer patients as the standard.
(2) The invention adopts the concept of using Rongkegang to implement blocking and enclosing on the tumor, and does not attack or collide, and does not harm the body, and does not attack or poison with poison, and the first medicine can activate the self-defense function of immune system, and the second medicine can implement blocking and enclosing on the tumor, and can inhibit its metastasis, and the third medicine can go deep into the deep layer of viscera, slowly remove the toxicity of the tumor, reduce its vitality, and then eliminate it intensively.
The medicine of the invention has the following effects:
(1) the medicine disclosed by the invention can strengthen the immune function, dissipate hardness and soften knot, dredge collaterals and relieve pain, clear away heat and toxic materials, cool blood, sooth liver and relieve depression, promote yang qi and has a unique curative effect on cervical cancer.
(2) The medicine of the invention enriches the variety of Chinese herbal compound for treating malignant tumor, expands the range of raw materials of the Chinese herbal compound, and avoids the centralized predation of Chinese herbal resources.
(3) The medicine of the invention is hardly suitable for rare and precious medicinal materials, has low cost and is convenient to carry and take.
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto.
Example 1
Weighing 30kg of astragalus membranaceus, 18kg of bighead atractylodes rhizome, 18kg of poria cocos, 8kg of scorpion, 8kg of Sichuan feet, 10kg of paniculate swallowwort root, 10kg of rhizoma notopterygii silkworm, 18kg of turtle shell, 18kg of oyster, 8kg of radix bupleuri, 10kg of radix paeoniae alba, 12kg of sida acuta, 12kg of paris polyphylla, 4kg of prepared monkshood, 8kg of aspongopus and 15kg of emilia sonchifolia, respectively crushing the raw materials into 50-100 meshes, uniformly mixing the crushed raw materials, and subpackaging according to the amount of 0.3g of medicine per capsule to obtain the capsule for adjuvant treatment of cervical cancer.
Example 2
Weighing 30kg of astragalus membranaceus, 18kg of bighead atractylodes rhizome, 18kg of poria cocos, 8kg of scorpion, 8kg of Sichuan feet, 10kg of paniculate swallowwort root, 10kg of rhizoma notopterygii silkworm, 18kg of turtle shell, 18kg of oyster, 8kg of radix bupleuri, 10kg of radix paeoniae alba, 12kg of sida acuta, 12kg of paris polyphylla, 4kg of prepared monkshood, 8kg of aspongopus and 15kg of emilia sonchifolia, adding 8-12 times of 70-DEG C hot water for soaking for 1.5h, heating to boiling, decocting for 2 hours, filtering, drying filtrate to obtain dry medicinal powder, and crushing the dry medicinal powder into 50-100 meshes to obtain the medicine for assisting in treating cervical.
Inhibition experiment of cervical cancer tumor cell line
1. Raw materials
The powder obtained in example 2 was dissolved in water to prepare a high concentration drug solution having a specific gravity of 1.2.
2. Test object
The Kunming mouse has the weight of 18-22 g, and the inoculated tumor strain is a mouse cervical cancer U14 cell strain.
3. Experimental procedure
24h after tumor inoculation, the mice were divided into 4 groups of 15 mice each, including a control group (saline), a low dose test group (100mg/kg), a high dose test group (500mg/kg) and a positive control group (CTX, 25 mg/kg). Wherein, the control group and the experimental group are administrated by intragastric administration, the CTX control group is administrated by intraperitoneal injection, all mice are administrated 1 time a day, and the mice are killed after being continuously administrated for 10 days.
Splenocytes were taken after sacrifice and tested for cytokine secretion (IL-2, IFN-. gamma., IL-10, IL 4).
4. Results of the experiment
TABLE 1 Effect of the Chinese medicinal composition of the present invention on inhibiting cervical cancer
Group of Average tumor weight (g) Mean tumor inhibition/%)
Control group 3.02±0.19 -
Low dose group 1.83±0.41 39.4
High dose group 1.72±0.36 43.0
Positive control group 1.55±0.19 48.7
(P < 0.05 compared with control)
The results show that the traditional Chinese medicine composition has an obvious inhibiting effect on cervical cancer tumor tissues, and the effect of a high-dose group is only slightly lower than that of common Cyclophosphamide (CTX), so that the traditional Chinese medicine composition has a high practical value.
TABLE 2 Effect of the Chinese medicinal composition of the present invention on the secretion of cytokines from mouse splenocytes
Group of IL-2(pg/ml) IFN-γ(pg/ml) IL-10(pg/ml) IL4(pg/ml)
Control group 15.4±3.5 8.9±1.6 128.3±6.1 49.6±2.5
Low dose group 17.6±3.3 9.7±1.8 114.5±8.1 44.3±2.4
High dose group 22.7±4.5 13.1±2.0 96.2±10.3 38.7±2.9
Positive control group 11.6±2.6 8.2±1.1 130.8±6.8 53.3±3.2
(P < 0.05 compared with control)
As can be seen from the results in table 2, although the tumor-inhibiting effect of the CTX-positive control group is better, it mostly acts in a form of directly killing tumor cells, and is liable to damage other cells of the body, especially immune cells. On the contrary, the traditional Chinese medicine composition disclosed by the invention is relatively mild in effect, can effectively improve the homeostatic imbalance of cell factors secreted by spleen cells, has a promoting effect on the autoimmunity of an organism, is expected to reduce the side effects generated by treatment, and is a safer and more effective treatment medicine.
Clinical observation experiment
90 patients with cervical cancer were selected, 23 below 55 years old, 67 above 55 years old, 41 women, 49 men, 52 patients in stage IIA, and 38 patients in stage IIB.
After operation, a patient takes the capsule prepared in the embodiment 1 of the invention 2 capsules each time, 3 times a day, 1 month is a treatment course, and the capsule is continuously taken for 6 treatment courses; patients after operation do not receive radiotherapy and chemotherapy.
One year after operation, 51 survivors of patients in IIA stage, the survival rate is about 98 percent, 12 relapses, and the relapse rate is about 23 percent; in stage IIB, 33 patients survive, the survival rate is about 87%, 14 patients relapse, and the relapse rate is about 37%. The results show that after the traditional Chinese medicine composition is taken, the survival rate and the recurrence rate of the cervical cancer patient are greatly improved compared with the average level of China, and the life quality and the life cycle of the patient can be effectively improved.
It should be understood that the embodiments of the present invention are merely illustrative of the present invention and are not to be construed as limiting the scope of the present invention. The invention is not limited to the embodiments described above, but rather, the invention may be embodied in many different forms.

Claims (8)

1. The medicine for adjuvant therapy of cervical cancer is characterized by comprising the following components in parts by mass:
20-50 parts of astragalus membranaceus, 15-20 parts of bighead atractylodes rhizome, 15-20 parts of poria cocos, 5-10 parts of scorpion, 5-10 parts of ligusticum wallichii, 8-12 parts of paniculate swallowwort root, 7-12 parts of rhizoma notopterygii, 15-20 parts of turtle shell, 15-20 parts of oyster, 5-10 parts of radix bupleuri, 7-12 parts of radix paeoniae alba, 10-15 parts of sida acuta, 10-15 parts of paris polyphylla, 3-5 parts of prepared monkshood, 5-10 parts of aspongopus and 10-20 parts of emilia sonchifolia.
2. The method of claim 1 for preparing a medicament for adjunctive treatment of cervical cancer, comprising:
weighing the components in parts by weight, respectively grinding the components to 50-100 meshes, and uniformly mixing to obtain the medicine for the adjuvant treatment of cervical cancer.
3. The method of claim 1 for preparing a medicament for adjunctive treatment of cervical cancer, comprising:
weighing the components in parts by weight, adding hot water for soaking, heating to boil, decocting, filtering and drying to obtain dry medicine powder, and grinding to 50-100 meshes to obtain the medicine for adjuvant treatment of cervical cancer.
4. The method for preparing a medicine for adjuvant therapy of cervical cancer according to claim 3, wherein the amount of the hot water is 8-12 times of the total weight of the ingredients.
5. The method for preparing a medicament for the adjunctive treatment of cervical cancer according to claim 3, wherein the hot water temperature is 50-90 ℃.
6. The method for preparing a medicament for the adjunctive treatment of cervical cancer according to claim 3, wherein the soaking time is 1-2 hours.
7. The method for preparing a medicament for the adjunctive treatment of cervical cancer according to claim 3, wherein the decoction time is 1.5-3 hours.
8. A pharmaceutical preparation which is a capsule, a pill, a granule, a tablet or an oral liquid, and is characterized by comprising the medicament for the adjuvant treatment of cervical cancer according to claim 1 and auxiliary materials necessary for the preparation molding.
CN202011244548.2A 2020-11-10 2020-11-10 Medicine for adjuvant therapy of cervical cancer and preparation method thereof Pending CN112190649A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011244548.2A CN112190649A (en) 2020-11-10 2020-11-10 Medicine for adjuvant therapy of cervical cancer and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011244548.2A CN112190649A (en) 2020-11-10 2020-11-10 Medicine for adjuvant therapy of cervical cancer and preparation method thereof

Publications (1)

Publication Number Publication Date
CN112190649A true CN112190649A (en) 2021-01-08

Family

ID=74034556

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011244548.2A Pending CN112190649A (en) 2020-11-10 2020-11-10 Medicine for adjuvant therapy of cervical cancer and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112190649A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127798A (en) * 2013-05-02 2014-11-05 河北以岭医药研究院有限公司 Application of traditional Chinese medicine composition in preparation of medicine used for inhibiting metastasis of cancer cells to peritoneum
CN105902751A (en) * 2016-06-30 2016-08-31 贵州中草医医院 Traditional Chinese medicine composition for treating cervical cancer
CN107802717A (en) * 2017-11-11 2018-03-16 四川易创生物科技有限公司 A kind of new medicine composition for treating cervical carcinoma and preparation method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127798A (en) * 2013-05-02 2014-11-05 河北以岭医药研究院有限公司 Application of traditional Chinese medicine composition in preparation of medicine used for inhibiting metastasis of cancer cells to peritoneum
CN105902751A (en) * 2016-06-30 2016-08-31 贵州中草医医院 Traditional Chinese medicine composition for treating cervical cancer
CN107802717A (en) * 2017-11-11 2018-03-16 四川易创生物科技有限公司 A kind of new medicine composition for treating cervical carcinoma and preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
董柏祥: "扶正解毒汤治疗癌症晚期52例", 《山东中医杂志》 *

Similar Documents

Publication Publication Date Title
CN101401915A (en) Chinese medicine formulation for treating cancer and preparation method thereof
CN111375010A (en) A Chinese medicinal composition with effects of strengthening body resistance, consolidating constitution, nourishing liver, invigorating kidney, and enhancing immunity
CN101091769B (en) Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method
CN115837065B (en) Traditional Chinese medicine composition and application thereof
CN111097030A (en) Traditional Chinese medicine composition for treating tumors and relieving tumor pain and preparation method thereof
CN111298019A (en) Traditional Chinese medicine for treating tachyarrhythmia
CN102973758A (en) Traditional Chinese medicine composition for treating depression
CN100386106C (en) Medicine for treating acne and its preparation
CN104257883A (en) Traditional Chinese medicine composition for treating leucopenia after chemotherapy
CN107596331A (en) A kind of Chinese medicine preparation and preparation method for treating stomach cancer
CN112190649A (en) Medicine for adjuvant therapy of cervical cancer and preparation method thereof
CN101810667A (en) Medicine composition for auxiliary treatment of cancer
CN112294940A (en) Traditional Chinese medicine composition for treating tumors and application thereof
CN114588240B (en) Traditional Chinese medicine composition for treating colorectal cancer and preparation method and application thereof
CN103028079A (en) Pharmaceutical composition for preventing and treating brain tumor and preparation method
CN102784344B (en) Traditional Chinese medicine preparation for treating pulmonary tuberculosis
CN101721610B (en) Medicine for treating tumors
CN114404490B (en) Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method
CN111956759B (en) Tibetan medicine composition for adjuvant treatment of lung cancer and preparation method thereof
CN110960651B (en) Traditional Chinese medicine preparation with mammary gland hyperplasia resisting effect and preparation method and application thereof
CN107362296B (en) Medicine for treating benign tumor of skin and preparation method thereof
CN110123896B (en) Pharmaceutical composition for adjuvant treatment of tumor and preparation method thereof
CN109620944B (en) A Chinese medicinal composition with effects of dispelling pathogenic wind, removing dampness, strengthening tendons and bones, and its preparation method
CN101829219A (en) Periplaneta Americana pharmaceutical composition for treating ulcerative colitis and preparation method thereof
CN107802681B (en) Composition for improving clinical symptom sign of HIV infected person

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210108